Innovita Biological Technology Co., Ltd. (SHA:688253)
China
· Delayed Price · Currency is CNY 34.80
+1.16 (3.45%)
Mar 6, 2026, 4:00 PM EST
SHA:688253 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Revenue | 422.03 | 621.39 | 478.02 | 446.62 | 326.91 | Upgrade
|
| Revenue Growth (YoY) | -32.08% | 29.99% | 7.03% | 36.62% | -68.48% | Upgrade
|
| Cost of Revenue | - | 127.53 | 140.51 | 173.94 | 77.24 | Upgrade
|
| Gross Profit | 422.03 | 493.86 | 337.51 | 272.67 | 249.67 | Upgrade
|
| Selling, General & Admin | - | 149.62 | 99.11 | 90.84 | 83.96 | Upgrade
|
| Research & Development | - | 97.17 | 53.11 | 72.18 | 31.11 | Upgrade
|
| Other Operating Expenses | 261.51 | 3.01 | 1.44 | 8.89 | 2.87 | Upgrade
|
| Operating Expenses | 261.51 | 253.83 | 158.57 | 178.08 | 117.58 | Upgrade
|
| Operating Income | 160.53 | 240.03 | 178.94 | 94.59 | 132.09 | Upgrade
|
| Interest Expense | - | -0.11 | -0.2 | -0.41 | -0.13 | Upgrade
|
| Interest & Investment Income | - | 30.74 | 24.57 | 12.11 | 3.59 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.14 | 0.57 | 42.65 | -9.76 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.1 | -3.92 | 0.34 | -0.6 | -0.11 | Upgrade
|
| EBT Excluding Unusual Items | 160.62 | 267.87 | 204.22 | 148.35 | 125.68 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 7.46 | 9.15 | 2.23 | 0.89 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.1 | -0.01 | 0.01 | - | Upgrade
|
| Asset Writedown | - | - | -19.54 | - | -0 | Upgrade
|
| Other Unusual Items | - | 1.29 | 4.54 | 13.92 | 11.24 | Upgrade
|
| Pretax Income | 160.62 | 276.53 | 198.36 | 164.51 | 137.81 | Upgrade
|
| Income Tax Expense | 14.58 | 29.67 | 24.41 | 13.82 | 17.65 | Upgrade
|
| Earnings From Continuing Operations | 146.04 | 246.86 | 173.95 | 150.68 | 120.16 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | 0.09 | Upgrade
|
| Net Income | 146.04 | 246.86 | 173.95 | 150.68 | 120.25 | Upgrade
|
| Net Income to Common | 146.04 | 246.86 | 173.95 | 150.68 | 120.25 | Upgrade
|
| Net Income Growth | -40.84% | 41.92% | 15.44% | 25.31% | -78.96% | Upgrade
|
| Shares Outstanding (Basic) | 136 | 136 | 136 | 122 | 102 | Upgrade
|
| Shares Outstanding (Diluted) | 136 | 136 | 136 | 122 | 102 | Upgrade
|
| Shares Change (YoY) | 0.08% | 0.36% | 11.83% | 19.24% | 2.90% | Upgrade
|
| EPS (Basic) | 1.07 | 1.81 | 1.28 | 1.24 | 1.18 | Upgrade
|
| EPS (Diluted) | 1.07 | 1.81 | 1.28 | 1.24 | 1.18 | Upgrade
|
| EPS Growth | -40.88% | 41.41% | 3.23% | 5.08% | -79.55% | Upgrade
|
| Free Cash Flow | - | 269.31 | 242.89 | 68.71 | 42.52 | Upgrade
|
| Free Cash Flow Per Share | - | 1.98 | 1.79 | 0.56 | 0.42 | Upgrade
|
| Dividend Per Share | - | 0.560 | 0.400 | 0.166 | - | Upgrade
|
| Dividend Growth | - | 40.00% | 140.96% | - | - | Upgrade
|
| Gross Margin | 100.00% | 79.48% | 70.60% | 61.05% | 76.37% | Upgrade
|
| Operating Margin | 38.04% | 38.63% | 37.43% | 21.18% | 40.41% | Upgrade
|
| Profit Margin | 34.61% | 39.73% | 36.39% | 33.74% | 36.79% | Upgrade
|
| Free Cash Flow Margin | - | 43.34% | 50.81% | 15.38% | 13.01% | Upgrade
|
| EBITDA | 179.22 | 258.72 | 200.92 | 111.08 | 145.29 | Upgrade
|
| EBITDA Margin | 42.47% | 41.64% | 42.03% | 24.87% | 44.45% | Upgrade
|
| D&A For EBITDA | 18.7 | 18.7 | 21.98 | 16.49 | 13.21 | Upgrade
|
| EBIT | 160.53 | 240.03 | 178.94 | 94.59 | 132.09 | Upgrade
|
| EBIT Margin | 38.04% | 38.63% | 37.43% | 21.18% | 40.41% | Upgrade
|
| Effective Tax Rate | 9.08% | 10.73% | 12.31% | 8.40% | 12.80% | Upgrade
|
| Revenue as Reported | - | 621.39 | 478.02 | 446.62 | 326.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.